Comparing nebulized amphotericin B and saline for chronic pulmonary aspergillosis treatment
Official title: A Randomized Controlled Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Increasing Time to Relapse in Patients With Chronic Pulmonary Aspergillosis Treated With 12 Months of Oral Itraconazole
Run by Post Graduate Institute of Medical Education and Research, Chandigarh · NCT06447402 · Data updated 2026-11-12
This study is testing if a nebulized form of amphotericin B can help people with chronic pulmonary aspergillosis feel better compared to using saline after they've already been treated with oral itraconazole.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 196 (estimated) |
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh Academic / other |
| Locations | 1 site (Chandigarh, Chandigarh) |
| Status | Recruiting |
| Started | June 3, 2024 |
| Main results expected | May 1, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | September 22, 2026 |
| Trial ID | NCT06447402 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with chronic pulmonary aspergillosis who have completed 12 months of oral itraconazole therapy.
✕Probably not a fit
Patients currently on immunosuppressive drugs or with active pulmonary infections will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial aims to evaluate the effectiveness of nebulized amphotericin B compared to nebulized normal saline as a maintenance therapy for patients with chronic pulmonary aspergillosis (CPA) who have previously been treated with oral itraconazole. The study will involve patients who have completed 12 months of itraconazole therapy, assessing the safety and efficacy of the nebulized treatment approach. Given the significant burden of CPA and the limitations of current therapies, this trial seeks to provide a potentially more effective treatment option for this challenging condition.
Why it matters
Potential benefit: If successful, this study could offer a more effective maintenance therapy for patients with chronic pulmonary aspergillosis, potentially improving their quality of life and reducing mortality.
How similar studies have gone: Previous studies have indicated that nebulized amphotericin B may be non-inferior to oral itraconazole, but this approach is still being evaluated in larger populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * consecutive subjects with CPA who have received 12 months therapy with oral itraconazole Exclusion Criteria: (i) failure to provide informed consent; (ii) patients on immunosuppressive drugs, intake of \>10 mg prednisolone (or equivalent) for at least 3 weeks in last 3 months, or a diagnosis of human immunodeficiency virus syndrome, ; (iii) subjects with active pulmonary infection due to mycobacterium tuberculosis or mycobacteria other than tuberculosis (MOTT); (iv) subjects with others forms of pulmonary aspergillosis (subacute and acute invasive aspergillosis); (v) pregnancy.
Where it's running
-
Chest clinic
Chandigarh, Chandigarh, India Recruiting
Study contacts
- Study coordinator: Inderpaul S Sehgal, MD, DM
- Email: inderpgi@outlook.com
- Phone: 91-172-2756823
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Assessing the impact of Chronic Pulmonary Aspergillosis on health and well-being
This study is trying to create a new questionnaire to help understand how Chronic Pulmonary Aspergillosis affects the daily lives of patients.
-
Comparing oral itraconazole alone versus with glucocorticoids for lung disease overlap
This study tests whether taking oral itraconazole alone or with glucocorticoids helps people with both Chronic Pulmonary Aspergillosis and Allergic Bronchopulmonary Aspergillosis feel better.
-
Comparing two treatments for Chronic Pulmonary Aspergillosis
This study is testing if a combination of two treatments can help people with Chronic Pulmonary Aspergillosis feel better compared to using just one of the treatments alone.
-
PCR testing in blood and lung washings to monitor invasive pulmonary aspergillosis
This will test whether repeated PCR tests for Aspergillus fumigatus in blood and bronchoalveolar lavage fluid can track treatment response in adults with invasive pulmonary aspergillosis.
-
Breath analysis to detect fungal infections in leukemia patients
This study is testing if analyzing breath samples can help doctors detect fungal infections in leukemia patients who are at high risk due to their treatment.
-
Early diagnosis of invasive lung aspergillosis
This study is trying to see if new tests can help doctors diagnose lung infections caused by fungus earlier in critically ill patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.